Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE.
Fiche publication
Date publication
juin 2018
Journal
Annals of surgical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HEYD Bruno
Tous les auteurs :
Mercier F, Bakrin N, Bartlett DL, Goere D, Quenet F, Dumont F, Heyd B, Abboud K, Marolho C, Villeneuve L, Glehen O, ,
Lien Pubmed
Résumé
Ovarian cancer is the most common deadly cancer of gynecologic origin. Patients often are diagnosed at advanced stage with peritoneal metastasis. There are many rare histologies of ovarian cancer; some have outcomes worse than serous ovarian cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can be considered for patients with recurrence. This study was designed to assess the impact of CRS and HIPEC on survival of patient with peritoneal metastasis from rare ovarian malignancy.
Mots clés
Adolescent, Adult, Aged, Aged, 80 and over, Carcinoma, Endometrioid, secondary, Cytoreduction Surgical Procedures, adverse effects, Disease-Free Survival, Female, Follow-Up Studies, Granulosa Cell Tumor, secondary, Humans, Hyperthermia, Induced, Lymphatic Metastasis, Middle Aged, Neoplasms, Cystic, Mucinous, and Serous, secondary, Neoplasms, Germ Cell and Embryonal, secondary, Ovarian Neoplasms, pathology, Peritoneal Neoplasms, secondary, Rare Diseases, pathology, Retrospective Studies, Survival Rate, Teratoma, secondary, Treatment Outcome, Young Adult
Référence
Ann. Surg. Oncol.. 2018 Jun;25(6):1668-1675